← Back to patent-cliff list
Calderasib
Tier C — Watch / tradeCalderasib
MSD (Merck Sharp & Dohme)
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KRAS G12C
Indications (approved)：Non-small cell lung cancer, Colorectal cancer, Colon cancer, Rectal cancer, Lung cancer, Neoplasm, Hepatic function decline, Renal impairment
Regional status
US
Phase III
2024-04-04
EU
Phase III
2024-05-24
China
Phase III
2024-05-24
Japan
Phase III
2024-05-24
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Calderasib?
Approved indications include: Non-small cell lung cancer, Colorectal cancer, Colon cancer, Rectal cancer, Lung cancer, Neoplasm, Hepatic function decline, Renal impairment.
When does the Calderasib patent expire?
No public expiry year is available for Calderasib yet; this page updates once verified.
How do I get a quote for Calderasib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01